Human epidermal growth factor receptor 2 testing in gastric carcinoma: Issues related to heterogeneity in biopsies and resections

Histopathology

Volumn 59, Issue 5, 2011, Pages 832-840

  Lee, Stephen ^a,b   de Boer, Willem Bastiaan ^a,b   Fermoyle, Soraya ^c   Platten, Michael ^a   Kumarasinghe, Marian Priyanthi ^a,b  

^a PATHWEST LABORATORY MEDICINE   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c ROYAL PERTH HOSPITAL   (Australia)

Author keywords

Gastric cancer; Gastric dysplasia; HER2; Heterogeneity; Immunohistochemistry; In situ hybridization

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ARTICLE; CANCER GRADING; CANCER INVASION; CANCER LOCALIZATION; CANCER SURGERY; DISEASE ASSOCIATION; DISEASE MARKER; FALSE NEGATIVE RESULT; GASTRECTOMY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; STOMACH CARCINOMA; STOMACH EPITHELIUM; TUMOR BIOPSY; TUMOR CELL;

ADENOCARCINOMA; BIOPSY; GASTRECTOMY; GENES, ERBB-2; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; PRECANCEROUS CONDITIONS; RECEPTOR, ERBB-2; REPRODUCIBILITY OF RESULTS; STOMACH NEOPLASMS;

EID: 81555209827     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2011.04017.x     Document Type: Article

References (19)

1. Ohtsu A. Chemotherapy for metastatic gastric cancer: past, present, and future. J. Gastroenterol. 2008; 43; 256-264.
2. Hofmann M, Stoss O, Shi D et al. Assessment of a HER-2 scoring system for gastric cancer: results from a validating study. Histopathology 2008; 52; 797-805.
3. Gravalos C, Jimeno A. Her2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann. Oncol. 2008; 19; 523-529.
4. Bang Y-J, Van Cutsem E, Feyeereislova A et al. Tratuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010; 376; 687-697.
5. Therapeutic Goods Administration. Herceptin Approved Product Information, September 2010. Canberra: Therapeutic Goods Administration, 2010.
6. Bilious M, Osamura RY, Rushcoff J et al. Her-2 amplification is highly homogenous in gastric carcinoma [Comment]. Hum. Pathol. 2010; 41; 304-305.
7. Bang Y-J, Chung HC, Xu JM et al. Pathological features of advanced gastric cancer: relationship to human epidermal growth factor receptor 2 positivity in the global screening programme of the ToGA trial. J. Clin. Oncol. 2009; 27(Suppl. 15s); Abstract 4556.
8. Papouchado BG, Myles J, Lloyd RV et al. Silver in situ hybridization (SISH) for determination of HER2 gene status in breast carcinoma: comparison with FISH and assessment of interobserver reproducibility. Am. J. Surg. Pathol. 2010; 34; 767-776.
9. Cottu PH, Asselah J, Lae M et al. Intratumoral heterogeneity of HE/2neu expression and its consequences for the management of advanced breast cancer. Ann. Oncol. 2008; 19; 596-597.
10. Brunelli M, Manfrin E, Martignoni G et al. Genotypic intratumoral heterogeneity in breast carcinoma with HER2/neu amplification. Am. J. Clin. Pathol. 2009; 131; 678-682.
11. Wu JM, Halushka MK, Argani P. Intratumoral heterogeneity of HER-2 gene amplification and protein overexpression in breast cancer. Hum. Pathol. 2010; 41; 914-917.
12. Marx AH, Tharun L, Muth J et al. Her-2 amplification is highly homogenous in gastric carcinoma. Hum. Pathol. 2009; 40; 769-777.
13. Grabsch H, Sivakumar S, Gray S, Gabbert HE, Muller W. HER2 expression in gastric cancer: rare, heterogeneous and of no prognostic value-conclusions from 924 cases of two independent series. Cell. Oncol. 2010; 32; 57-65.
14. Kumarasinghe AP, de Boer WB, Bateman AC, Kumarasinghe MP. DNA mismatch repair enzyme immunohistochemistry in colorectal cancer: a comparison of biopsy and resection material. Pathology 2010; 42; 414-420.
15. Tanner M, Hollmen M, Junttila TT et al. Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann. Oncol. 2005; 16; 273-278.
16. Allgayer H, Babic R, Gruetzner KU, Tarabichi A, Schildberg FW, Heiss MM. c-erbB-2 is of independent prognostic relevance in gastric cancer and is associated with the expression of tumor-associated protease systems. J. Clin. Oncol. 2000; 18; 2201-2209.
17. Ross JS, McKenna B. The HER-2/neu oncogene in tumors of the gastrointestinal tract. Cancer Invest. 2001; 19; 554-568.
18. Roses RE, Paulson EC, Sharma A et al. HER-2/neu overexpression as a predictor for the transition from in situ to invasive breast cancer. Cancer Epidemiol. Biomark. Prev. 2009; 18; 1386-1389.
19. Sepulveda AR, Aisner D. Molecular basis of diseases of the gastrointestinal tract. In Coleman WB, Tsongalis GJ eds. Molecular pathology. London: Elsevier Inc., 2008; 365-372.